Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign that ran in the EU, ...

The Federal Trade Commission (FTC) and several US states have accused Martin Shkreli of violating a lifetime restraining ...

A phase 2/3 trial of BioNTech's immunotherapy for head and neck cancer, BNT113, has failed to meet its objective, but the ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Robbie Tyrie, founder and managing director of Torridon ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...

Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ...

Aspen Neuroscience, which is developing stem cell therapies for Parkinson's disease, has filed an IPO to raise additional ...

Women and girls with autoimmune diseases are much more likely to have their condition misdiagnosed as psychiatric or ...

Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...